ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Some Anemia Treatment Agents Increase Risk Of Blood Clots And Death In Cancer Patients
Using erythropoiesis-stimulating agents (ESAs) in the
treatment of anemia increases the risk of venous thromboembolism (VTE)
and death among cancer patients, according to an article in the
February 27, 2008 issue of JAMA.
ESAs are a class of drugs that promote red blood cell production in the
body. The ESAs erythropoietin and darbepoetin are commonly
used in patients with cancer to treat anemia. Previous studies
indicated that there might be a higher risk of VTE, blood clots in the
deep veins of the legs of lungs. However, these studies did not
conclude if an associated increased risk of death was created.
To determine the effect on mortality in these patients, Charles L.
Bennett, M.D., Ph.D., of the Northwestern University Feinberg School of
Medicine, Chicago, and colleagues reviewed phase 3 trials, examining
instances of VTE and death with ESA administration for treatment of
anemia in cancer patients.
51 trials were identified with 13,611 patients. Analysis of survivial
within the data showed that patients who were treated with ESA were
significantly
more likely to die than patients in the placebo control group. 38
trials were evaluated for VTE, including 8,172 patients. In the
analysis, the investigators found that a significantly increased risk
of VTE was present in patients treated with ESA versus the control
population.
This could have important implications, considering how common
treatment using ESAs is. The authors write: "These risks are important
given the prevalence of ESA use as a supportive care drug among
patients with cancer as well as the dissemination of a series of safety
advisories by the Food and Drug Administration (FDA) and ESA
manufacturers."
They continue: "Safety concerns account in large part for changes
observed in patterns of use, reimbursement policies, clinical
guidelines, and FDA-approved package inserts pertaining to ESAs in the
oncology setting. Our findings, in conjunction with basic science
reports on erythropoietin and erythropoietin receptors in solid
cancers, raise concern about ESA safety for patients with cancer."
Venous Thromboembolism and Mortality Associated With
Recombinant Erythropoietin and Darbepoetin Administration for the
Treatment of Cancer-Associated Anemia
harles L. Bennett, MD, PhD; Samuel M. Silver, MD, PhD; Benjamin
Djulbegovic, MD, PhD; Athena T. Samaras, BA; C. Anthony Blau, MD; Kara
J. Gleason, BS; Sara E. Barnato, MD; Kathleen M. Elverman; D. Mark
Courtney, MD; June M. McKoy, MD, MPH, JD; Beatrice J. Edwards, MD; Cara
C. Tigue, BA; Dennis W. Raisch, PhD; Paul R. Yarnold, PhD; David A.
Dorr, MD, MS; Timothy M. Kuzel, MD; Martin S. Tallman, MD; Steven M.
Trifilio, RPh; Dennis P. West, PhD; Stephen Y. Lai, MD, PhD; Michael
Henke, MD
JAMA. 2008;299(8):914-924.
Click
Here For Abstract
Written by Anna Sophia McKenney
Copyright: Start Sanatate
Not to be reproduced without permission of Start Sanatate
Unii agenþi de anemie tratament creºte riscul de cheaguri de sânge ºi de moarte la pacienþi cu cancer - Some Anemia Treatment Agents Increase Risk Of Blood Clots And Death In Cancer Patients - articole medicale engleza - startsanatate